Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Pharmacogenomics Market Revenue Growth On Track For A 10.2% CAGR Through 2030#_x000D_
The pharmacogenomics market has seen significant expansion in recent years. This market is set to increase from $9.84 billion in 2025 to $10.85 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this expansion has been driven by factors such as increasing genomic research activities, the development of targeted therapies, a rising prevalence of chronic diseases, advancements in sequencing technologies, and the growing availability of genetic testing services._x000D_
_x000D_
The pharmacogenomics market is poised for substantial expansion over the next few years. It is projected to attain a value of $15.98 billion in 2030, growing at a compound annual growth rate (CAGR) of 10.2%. The anticipated surge throughout the forecast period stems from escalating investments in precision medicine programs, the increasing uptake of AI-driven genomic analysis, the broadened application of pharmacogenomics in oncology and cardiology, a heightened focus on individualized drug development, and continuous advancements in bioinformatics platforms. Noteworthy trends for this period encompass a greater adoption of personalized medicine approaches, the rising utilization of genetic testing in drug selection, deeper integration of pharmacogenomic data into clinical workflows, the expansion of companion diagnostics, and an enhanced emphasis on precision therapeutics._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Pharmacogenomics Market Growth Backed By Core Demand Fundamentals#_x000D_
The expansion of the pharmacogenomics market is anticipated to be driven by the rising incidence of chronic diseases. These are medical conditions that endure for prolonged durations, frequently throughout an individual’s life. The surge in chronic diseases can be attributed to the global population’s extended average lifespan, alongside the prevalent embrace of lifestyle risk factors like inactive habits, inadequate nutrition, and smoking. Pharmacogenomics provides a tailored treatment strategy for chronic ailments, considering unique genetic differences that influence how individuals react to medication. As an illustration, for the year 2025, the International Diabetes Federation, a Belgium-based health organization, noted that in 2024, around 589 million adults aged 20-79 were living with diabetes. This figure is forecasted to climb to 853 million by 2050, with over 4 in 5 diabetic adults residing in low and middle income countries. Consequently, the expanding prevalence of chronic diseases is fueling the development of the pharmacogenomics market._x000D_
_x000D_
#Pharmacogenomics Market Segment Trends And Revenue Contributors#_x000D_
The pharmacogenomics market covered in this report is segmented – _x000D_
_x000D_
1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies_x000D_
2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications_x000D_
3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing _x000D_
2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR _x000D_
3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis _x000D_
4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry) _x000D_
5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays_x000D_
6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools _x000D_
_x000D_
#Pharmacogenomics Market Growth Trends Reshaping The Competitive Landscape#_x000D_
Key companies active in the pharmacogenomics market are increasingly prioritizing artificial intelligence (AI) driven systems that manage drug-drug interactions (DDIs) at the genomic level, thereby enhancing medication safety, lessening adverse reactions, and enabling highly tailored prescribing. AI-powered pharmacogenetics engines are advanced digital systems that utilize artificial intelligence to analyze an individual’s genetic profile and forecast their response to specific medications. For example, in December 2024, PGxAI, a US-based artificial intelligence (AI) driven pharmacogenetics company, launched its Sirius model, an AI-powered pharmacogenetics engine that customizes drug selection, dosage, and drug-drug interaction management based on an individual’s genome. Sirius covers 730 drugs and 40 key pharmacogenes, allowing for much broader coverage than traditional pharmacogenomic solutions. This model is designed for use by hospital systems, diagnostic labs, and clinical research organizations, helping to mitigate adverse reactions and improve therapeutic outcomes._x000D_
_x000D_
#Pharmacogenomics Market Competitive Analysis Of Leading Industry Participants#_x000D_
Major companies operating in the pharmacogenomics market are Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Genomika Diagnósticos _x000D_
_x000D_
#View The Full Pharmacogenomics Market Report:#_x000D_
_x000D_
#Pharmacogenomics Market Geographic Spread And Regional Opportunities#_x000D_
North America was the largest region in the pharmacogenomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.